Mechano growth factor, or MGF, is a splice variant of IGF-1 formally designated IGF-1Ec. It is not a separate hormone but an alternative product of the same gene, generated by muscle tissue specifically in response to mechanical loading or damage. It is sold online as a research chemical and has no approved human use.
This guide situates MGF within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
What is MGF?
The IGF-1 gene does not produce a single product. Through alternative splicing it yields several isoforms with different C-terminal extensions, and MGF is the variant designated IGF-1Ec in humans.
Its distinguishing feature is where and when it appears. MGF expression rises in skeletal muscle following mechanical loading, stretch, or damage — it is the local response to the muscle being worked, not a circulating endocrine signal. Its actions are autocrine and paracrine: it acts on the tissue that produced it, at the site that produced it.
What the biology suggests
Preclinical research indicates MGF participates in muscle repair by helping activate satellite cells — the resident stem cell population that fuses with existing fibers to support growth and repair after loading.
The unique C-terminal peptide of MGF appears to carry activity distinct from IGF-1 receptor signaling alone, which is why it attracted separate interest rather than being treated as simply another IGF-1.
The mechanistic story is coherent: load the muscle, generate a local repair signal, activate the machinery that rebuilds it. That is a genuine and well-supported description of how muscle adapts to training.
Where the evidence stops
The step from that biology to an injected product is where the support disappears. The available research is preclinical — cell culture and animal models. There are no adequate human clinical trials establishing that injected MGF builds muscle, improves recovery, or is safe over any duration.
There is also a specific pharmacologic problem. MGF is a locally acting factor released in a precise place at a precise time in response to a specific stimulus. Injecting a systemic dose does not reproduce that spatial and temporal pattern, and the synthetic peptide's stability in circulation is poor. Delivering a local signal systemically is not the same intervention.
Notably, the reliable way to raise MGF expression in a given muscle is already available and requires no product: load that muscle. That is the stimulus the entire mechanism exists to respond to.
Regulatory status
MGF is not FDA-approved and is not an established compounding substance. Material sold under this name is an unregulated research chemical with unverified identity and purity. The pegylated variant is covered separately in our PEG-MGF guide, where the regulatory position differs in an important and frequently misreported way.
The honest summary for a patient: the biology is real, the injectable product is not supported by human evidence, and resistance training is the intervention that actually triggers this pathway.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering the GH/IGF-1 axis and muscle repair signaling, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →